Dominari Stock (NASDAQ:DOMH)


RevenueFinancialsChart

Previous Close

$1.26

52W Range

$1.14 - $3.20

50D Avg

$1.67

200D Avg

$1.97

Market Cap

$7.67M

Avg Vol (3M)

$12.83K

Beta

0.96

Div Yield

-

DOMH Company Profile


Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

26

IPO Date

Mar 18, 1980

Website

DOMH Performance


DOMH Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.04M--
Operating Income$-21.80M$-14.35M$-9.44M
Net Income$-22.88M$-38.57M$-6.92M
EBITDA$-21.80M$-5.83M$-11.32M
Basic EPS-$-7.23$-1.43
Diluted EPS-$-7.23$-1.43

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SNTISenti Biosciences, Inc.
KTTAPasithea Therapeutics Corp.
SPROSpero Therapeutics, Inc.
BOLTBolt Biotherapeutics, Inc.
ACHLAchilles Therapeutics plc
NXTCNextCure, Inc.
SABSSAB Biotherapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
ASMBAssembly Biosciences, Inc.
MNOVMediciNova, Inc.
TILInstil Bio, Inc.